- Trials with a EudraCT protocol (121)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
121 result(s) found for: Peritoneum.
Displaying page 1 of 7.
EudraCT Number: 2021-001417-36 | Sponsor Protocol Number: BluePIPAC | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:HOSPITAL CLINICO UNIVERSITARIO | |||||||||||||
Full Title: CLINICAL TRIAL PHASE IIB ON THE TREATMENT WITH PIPAC (PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY) IN PATIENTS WITH NON-RESECTABLE PERITONEAL CARCINOMATOSIS | |||||||||||||
Medical condition: Patient presenting unresectable peritoneal metastases from digestive system, ovary or primary peritoneal origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000655-40 | Sponsor Protocol Number: ACAPP | Start Date*: 2018-04-30 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: ADJUVANT CAPECITABINE IN HIGH RISK PSEUDOMYXOMA PERITONEI PATIENTS TREATED WITH CYTOREDUCTIVE SURGERY (CRS) AND HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) | |||||||||||||
Medical condition: PMP PSEUDOMYXOMA PERITONEI | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000823-24 | Sponsor Protocol Number: P-HIPEC | Start Date*: 2017-02-14 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | ||||||||||||||||||
Full Title: P-HIPEC CYTOREDUCTION PLUS HIPEC IN PATIENTS AFFECTED BY PERITONEAL CARCINOMATOSIS: A FEASIBILITY TRIAL | ||||||||||||||||||
Medical condition: peritoneal carcinomatosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005695-15 | Sponsor Protocol Number: NL56123.031.15 | Start Date*: 2017-07-14 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:NKI-AVL | ||||||||||||||||||||||||||||||||||||||
Full Title: Treatment of PERitoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the PERISCOPE II study | ||||||||||||||||||||||||||||||||||||||
Medical condition: Gastric cancer with peritoneal carcinomatosis or tumour positive cytology | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) DK (Ongoing) FI (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004847-19 | Sponsor Protocol Number: 69HCL17_0239 | Start Date*: 2018-05-23 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: | |||||||||||||
Medical condition: Peritoneal carcinomatosis of colorectal origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002877-27 | Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 | Start Date*: 2023-07-06 | ||||||||||||||||
Sponsor Name:Cancer Trials Ireland | ||||||||||||||||||
Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P... | ||||||||||||||||||
Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001112-53 | Sponsor Protocol Number: 20101129 | Start Date*: 2012-01-09 | |||||||||||||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, P... | |||||||||||||||||||||||
Medical condition: FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) ES (Completed) BE (Completed) NL (Completed) AT (Completed) DK (Prematurely Ended) IT (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006831-10 | Sponsor Protocol Number: 1199.15 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||||||||||||||||||||||||||||
Full Title: Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and pac... | ||||||||||||||||||||||||||||
Medical condition: Advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) SE (Completed) BE (Completed) PT (Completed) SK (Completed) DK (Completed) AT (Completed) NL (Completed) FI (Completed) PL (Completed) IT (Completed) GR (Completed) CZ (Completed) ES (Completed) GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000382-20 | Sponsor Protocol Number: DMPMtarget012 | Start Date*: 2012-04-24 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Peritoneal Mesothelioma: Optimize Outcomes by the Integration of new Prognostic Factors and Potential Therapeutic Targets in a Individualized Treatment based on Molecular Characterization and Chemo... | |||||||||||||
Medical condition: Patients affected by diffuse malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, without any factor precluding the performance of syste... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000518-39 | Sponsor Protocol Number: CO-338-014 | Start Date*: 2014-01-08 | |||||||||||||||||||||
Sponsor Name:Clovis Oncology, Inc. | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Se... | |||||||||||||||||||||||
Medical condition: Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) IT (Completed) ES (Ongoing) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017437-22 | Sponsor Protocol Number: CCPS5959 | Start Date*: 2010-02-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PERUGIA | |||||||||||||
Full Title: MANAGEMENT OF PRIMARY AND SECUNDARY PERITONEAL CARCINOMATOSIS FROM COLO-RECTAL CANCER, RECURRENT OVARIAN CANCER AND ABDOMINAL SARCOMATOSIS BY CYTOREDUCTIVE SURGERY PLUS HYPERTHERMIC INTRAPERITONEAL... | |||||||||||||
Medical condition: Peritoneal carcinomatosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003592-34 | Sponsor Protocol Number: IMGN853-0419 | Start Date*: 2021-12-21 | |||||||||||||||||||||
Sponsor Name:ImmunoGen, Inc. | |||||||||||||||||||||||
Full Title: PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Rece... | |||||||||||||||||||||||
Medical condition: Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) IT (Ongoing) DE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003394-18 | Sponsor Protocol Number: PIPAC2trial | Start Date*: 2016-10-14 | |||||||||||
Sponsor Name:Michael Bau Mortensen | |||||||||||||
Full Title: Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy - PIPAC-2 trial - | |||||||||||||
Medical condition: Peritoneal carcinomatosis (PC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000179-19 | Sponsor Protocol Number: IMGN853-0417 | Start Date*: 2020-07-07 | |||||||||||||||||||||
Sponsor Name:ImmunoGen, Inc. | |||||||||||||||||||||||
Full Title: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Recept... | |||||||||||||||||||||||
Medical condition: Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: IE (Completed) DE (Completed) BG (Completed) BE (Completed) IT (Ongoing) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000277-72 | Sponsor Protocol Number: ARRAY-162-311 | Start Date*: 2013-09-18 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or... | |||||||||||||
Medical condition: Recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) CZ (Completed) DE (Completed) IE (Prematurely Ended) FI (Completed) NO (Completed) NL (Completed) SE (Completed) PL (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004472-30 | Sponsor Protocol Number: MITO23 | Start Date*: 2015-12-02 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Randomized phase III trial on Trabectedin (ET-743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients | |||||||||||||
Medical condition: recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004060-11 | Sponsor Protocol Number: 0403 | Start Date*: 2016-04-25 | |||||||||||||||||||||
Sponsor Name:ImmunoGen, Inc. | |||||||||||||||||||||||
Full Title: FORWARD1: A Randomized, Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator?s Choice of Chemotherapy in Adults with Folate Recept... | |||||||||||||||||||||||
Medical condition: Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Primary Fallopian Tube Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) GB (Completed) BE (Completed) PL (Completed) BG (Prematurely Ended) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001211-75 | Sponsor Protocol Number: D0816C00002 | Start Date*: 2013-11-15 | ||||||||||||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||
Full Title: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Comple... | ||||||||||||||||||||||||||||
Medical condition: BRCA Mutated Platinum Sensitive Relapse (PSR) high grade Serous Ovarian Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Ongoing) FR (Ongoing) PL (Completed) DE (Completed) BE (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002860-42 | Sponsor Protocol Number: MITO25 | Start Date*: 2017-09-25 | |||||||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||||||||||||
Full Title: A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ov... | |||||||||||||||||||||||
Medical condition: Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: IT (Restarted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000560-37 | Sponsor Protocol Number: IOV-CAR-01-2020PIPAC | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:ISTITUTO ONCOLOGICO VENETO - IRCCS | |||||||||||||
Full Title: Pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal carcinomatosis. PIPAC-IOV study. Single-center, single-arm open-label phase II clinical trial | |||||||||||||
Medical condition: Peritoneal carcinomatosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.